Emerson Erik C. 4
4 · Apimeds Pharmaceuticals US, Inc. · Filed May 20, 2025
Insider Transaction Report
Form 4
Emerson Erik C.
DirectorChief Executive Officer
Transactions
- Award
Stock option (right to buy)
2025-05-16+347,279→ 347,279 totalExercise: $1.81Exp: 2035-05-16→ Common Stock, par value $0.01 per share (347,279 underlying) - Award
Common Stock, par value $0.01 per share
2025-05-16+750,000→ 750,000 total
Footnotes (1)
- [F1]Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant.